Market capitalization | $350.00k |
Enterprise Value | $10.22m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.08 |
P/S ratio (TTM) P/S ratio | 0.17 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | 76.05% |
Revenue (TTM) Revenue | $2.01m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Seelos Therapeutics, Inc.:
1 Analyst has issued a forecast Seelos Therapeutics, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 2.01 2.01 |
76%
76%
|
|
Gross Profit | 1.96 1.96 |
85%
85%
|
|
EBITDA | -30 -30 |
46%
46%
|
EBIT (Operating Income) EBIT | -30 -30 |
46%
46%
|
Net Profit | 4.09 4.09 |
105%
105%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio includes late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.
Head office | United States |
CEO | Raj Mehra |
Employees | 16 |
Founded | 1987 |
Website | www.seelostherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.